Adiponectin circulating levels and 10-year (2002–2012) cardiovascular disease incidence: the ATTICA Study

Ioannis Kyrou, Olga Tsantarlioti, Demosthenes B. Panagiotakos*, Constantine Tsigos, Ekavi Georgousopoulou, Christina Chrysohoou, Ioannis Skoumas, Dimitrios Tousoulis, Christodoulos Stefanadis, Christos Pitsavos,

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Purpose: Adiponectin is an adipokine with anti-inflammatory and cardiovascular-protective properties. Existing epidemiological evidence is conflicting on the exact relationship between adiponectin and long-term cardiovascular disease (CVD) risk. Our aim was to prospectively assess whether circulating adiponectin is associated with long-term incident CVD. Methods: A population-based, prospective study in adults (>18 years) without previous CVD history (ATTICA study). Circulating total adiponectin levels were measured at baseline (2001–2002) in a sub-sample (n = 531; women/men: 222/309; age: 40 ± 11 years) of the ATTICA cohort and complete 10-year follow-up data were available in 366 of these participants (women/men: 154/212; age: 40 ± 12 years). Results: After adjusting for multiple factors, including age, sex, body mass index, waist circumference, smoking, physical activity, Mediterranean diet adherence, hypertension, diabetes, and hypercholesterolemia, our logistic regression analysis indicates that an increase in circulating total adiponectin levels by 1 unit was associated with 36% lower CVD risk (relative risk [RR]: 0.64, 95% confidence interval [CI] 0.42–0.96; p = 0.03). Further adjusting for interleukin-6 plasma levels had no significant impact (RR: 0.60, 95% CI 0.38–0.94; p = 0.03), while additional adjustment for circulating C-reactive protein (CRP) modestly attenuated this association (RR: 0.63, 95% CI 0.40–0.99; p = 0.046). Conclusions: In our study, elevated circulating total adiponectin levels were associated with lower 10-year CVD risk in adults without previous CVD, independently of other established CVD risk factors. This association appeared to be modestly attenuated by CRP, yet was not mediated by interleukin-6 which is the main endocrine/circulating pro-inflammatory cytokine.

Original languageEnglish
Pages (from-to)542–552
Number of pages11
JournalEndocrine
Volume58
Issue number3
Early online date16 Oct 2017
DOIs
Publication statusPublished - 1 Dec 2017

Bibliographical note

© 2017 Springer International Publishing AG

Funding: Hellenic Cardiology Society (HCS2002) and the Hellenic Atherosclerosis Society (HAS2003)

Keywords

  • Adiponectin
  • ATTICA study
  • Cardiovascular disease
  • CVD risk

Fingerprint Dive into the research topics of 'Adiponectin circulating levels and 10-year (2002–2012) cardiovascular disease incidence: the ATTICA Study'. Together they form a unique fingerprint.

  • Cite this

    Kyrou, I., Tsantarlioti, O., Panagiotakos, D. B., Tsigos, C., Georgousopoulou, E., Chrysohoou, C., Skoumas, I., Tousoulis, D., Stefanadis, C., Pitsavos, C. (2017). Adiponectin circulating levels and 10-year (2002–2012) cardiovascular disease incidence: the ATTICA Study. Endocrine, 58(3), 542–552. https://doi.org/10.1007/s12020-017-1434-y